Patients younger than 45 years of age have superior 5-year survival in advanced esophageal cancer

Saddoughi, Sahar A.; Taswell, James; Spears, Grant M.; Harmsen, William S.; Allen, Mark S.; Blackmon, Shanda H.; Cassivi, Stephen D.; Nichols, Francis D.; Wigle, Dennis A.; Shen, K. Robert

doi:10.21037/shc.2019.07.01

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, some cancer types are inherently age- or gender-related e.g. a better prognosis subgroup of younger patients has been documented for ESCA [ 96 ]. Although in our analysis we only discarded CpG probes as associated with age or gender when this correlation had been observed in at least two cancer types, our analysis in such cancers might still suffer from overfiltering.…”

Section: Discussionmentioning

confidence: 99%

Deciphering the etiology and role in oncogenic transformation of the CpG island methylator phenotype: a pan-cancer analysis

Yates

Boeva

2022

Briefings in Bioinformatics

View full text Add to dashboard Cite

Numerous cancer types have shown to present hypermethylation of CpG islands, also known as a CpG island methylator phenotype (CIMP), often associated with survival variation. Despite extensive research on CIMP, the etiology of this variability remains elusive, possibly due to lack of consistency in defining CIMP. In this work, we utilize a pan-cancer approach to further explore CIMP, focusing on 26 cancer types profiled in the Cancer Genome Atlas (TCGA). We defined CIMP systematically and agnostically, discarding any effects associated with age, gender or tumor purity. We then clustered samples based on their most variable DNA methylation values and analyzed resulting patient groups. Our results confirmed the existence of CIMP in 19 cancers, including gliomas and colorectal cancer. We further showed that CIMP was associated with survival differences in eight cancer types and, in five, represented a prognostic biomarker independent of clinical factors. By analyzing genetic and transcriptomic data, we further uncovered potential drivers of CIMP and classified them in four categories: mutations in genes directly involved in DNA demethylation; mutations in histone methyltransferases; mutations in genes not involved in methylation turnover, such as KRAS and BRAF; and microsatellite instability. Among the 19 CIMP-positive cancers, very few shared potential driver events, and those drivers were only IDH1 and SETD2 mutations. Finally, we found that CIMP was strongly correlated with tumor microenvironment characteristics, such as lymphocyte infiltration. Overall, our results indicate that CIMP does not exhibit a pan-cancer manifestation; rather, general dysregulation of CpG DNA methylation is caused by heterogeneous mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%